While there was no differential benefit from anthracycline-based therapy in patients with HER2+ vs HER2− breast cancer in this study, those with tumor TOP2A-amplification (N = 92) (ratio >2) had a significantly improved RFS and OS with CEF. Here, ERBB2 is linked to breast carcinoma.